The acquisition of HI-Bio by Biogen has been completed. Together, we will be advancing our clinical development plans to deliver innovative treatments to patients in need. Follow @Biogen for the latest news and read about the acquisition: https://t.co/vAxZXUW8ew
This weekend, our team attended the @ATCMeeting to further discuss the recent positive felzartamab data in antibody-mediated rejection (AMR) in kidney transplant recipients recently featured in @NEJM. View the presentation here: https://t.co/BRG5SMhQQC
#ATC2024Philly
Thank you to our partners, advisors and everyone who made the conference a success! Read our presentations from the meeting here: https://t.co/zJ8VSU7k0j #ERA24#immunology#nephrology (3/3)
Last week, members of our team attended the 61st @ERAkidney Congress in Stockholm where we shared positive data on felzartamab in the treatment of both antibody-mediated rejection (AMR) in kidney transplant recipients and IgA nephropathy (IgAN). (1/3)
The results of the AMR study, presented by lead author Katharina Mayer, M.D., were simultaneously published in @NEJM. The data demonstrate the promise of our cell-depletion strategy in the treatment of AMR and other immune-mediated diseases. (2/3)
Today we announced a definitive agreement under which @biogen has agreed to acquire HI-Bio. The proposed acquisition combines expertise in immune-mediated indications with global development and commercial experience in rare diseases.
Read more: https://t.co/gFjsfrIMDC
Today is IgAN Awareness Day! IgAN is a serious, rare kidney disease, impacting more than 130,000 patients in the U.S. today. We're proud to work with investigators to advance therapies for patients in need. Thanks to the @IgANFoundation for their work! #IgANAware
It’s the 20th Anniversary IgAN Awareness Day! This year marks 2 decades of progress in working toward better treatment, support, and a cure for IgA Nephropathy. Let's continue to support each other on our #IgANjourney towards a brighter future! 🎉❤️💙
https://t.co/LGa1swMqGV
More than 60% of lupus patients will develop lupus nephritis and current treatments have limited efficacy. Our lead clinical candidate, felzartamab, presents a potential opportunity to treat IMDs like lupus nephritis and achieve better outcomes for patients in need. (2/2)
May is #LupusAwarenessMonth and today is #WorldLupusDay, a day dedicated to supporting patients, spreading awareness of and educating people about lupus. At HI-Bio, we’re committed to the development of therapies for rare, immune-mediated diseases including #LupusNephritis. (1/2)
Attending @ERAkidney’s Congress this May? We’ll be sharing oral presentations with data on our investigational agent felzartamab: interim results from the Phase 2 IGNAZ study in IgA nephropathy and Phase 2 investigator-sponsored study results in antibody-mediated rejection. (1/2)
We are excited to announce that the FDA has granted orphan drug designation for felzartamab, our investigational agent in development for the treatment of antibody-mediated rejection in kidney transplant recipients! More on this important step here: https://t.co/kgd2ODniKj
March is #NationalKidneyMonth and today is #WorldKidneyDay, a day to raise awareness of the importance of kidney health. At HI-Bio, we’re committed to the development of therapies for rare, immune-mediated diseases, and across four indications in kidney health. (1/2)
Today is #RareDiseaseDay, a day dedicated to raising awareness for patients impacted by rare diseases. At HI-Bio, we are developing targeted therapies to treat rare, immune-mediated disease (IMD) indications. (1/2)
Today, we’re pleased to announce our $95 million Series B to advance targeted therapies for immune-mediated diseases – bringing felzartamab, our clinically differentiated lead candidate, through clinical readouts and preparation for registrational studies. https://t.co/hpKxw9WANi
We enjoyed attending @ASNKidney’s annual Kidney Week meeting, where we presented final Phase 2 M-PLACE data. Thanks to our collaborators, advisors and everyone who made the event possible. You can read our posters and presentations from the meeting here: https://t.co/zJ8VSU7k0j
We are excited to announce that the FDA has granted Breakthrough Therapy designation for felzartamab for primary membranous nephropathy! Learn more about this important step forward: https://t.co/jZ7EyacCUd
Attending @ASNKidney’s Kidney Week? We’ll be sharing data on clinically differentiated anti-CD38 candidate felzartamab: posters on lupus nephritis study design and on mechanism, and an oral presentation of full Phase 2 results in primary membranous nephropathy. (1/2)